A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB
NCT: NCT05635747 · ENROLLING_BY_INVITATION
Brief Summary
Children with inadequate intestinal absorption due to loss of large amounts of small bowel require intravenous nutrition (feeding through the vein) to sustain hydration and nutrition to avoid starvation and dehydration; however, intravenous (IV) nutrition can lead to complications including liver failure. Tube feeding directly to the small intestine avoids the complications of IV nutrition, but fats are not fully digestible due to inadequate bowel function. We propose to predigest the fat using a small cartridge attached to the feeding tube to allow for rapid absorption with the possibility of reducing or eliminating the need for intravenous nutrition. Goal of the observational study is to determine safety and tolerability of Relizorb Enzyme Cartridge for an additional 90 days after the original trial
Frequently Asked Questions
What is A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB?
A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB is a clinical trial registered under NCT05635747. Current status: ENROLLING_BY_INVITATION.
What is the status of NCT05635747?
The current status of NCT05635747 (A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB) is: ENROLLING_BY_INVITATION.
When did A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB start?
A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB started on 2022-09-29.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.